MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Status Active, not recruiting

Clinical Trial Summary

Twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells (REIC)/Dikkopf (Dkk)-3 gene, on Days 1, 8, 22, and 50. Patients will also receive every 4 weekly intravenous infusions of nivolumab, 480 mg, starting on Day 2. Safety and anti-tumor activity will be monitored at regular intervals throughout the study.

Clinical Trial Description

This is a study of the efficacy and safety of MTG201 given by intratumoral injection to patients with malignant pleural mesothelioma who have failed front line chemotherapy. Patients will also receive IV infusions of nivolumab every 4 weeks. MTG201 is a replication incompetent adenovirus into which the gene for REIC/Dkk-3 has been inserted. The insertion of this gene has been shown to endow the adenovirus with anti-tumor activity and to result in enhanced anti-tumor immunity. MTG201, 3 x 10E12 vp, will be given by intratumoral injection on days 1, 8, 22 and 50. Nivolumab, 480 mg, will be given by IV infusion every 4 weeks until progression. Efficacy will be assessed by CT scans at 4 and 12 weeks, then every 3 months. Safety will be assessed by reported adverse events, periodic laboratory assessments, physical exams, vital signs. The pharmacokinetics and pharmacodynamics of MTG201 will be assessed periodically. Tumor biopsy will be obtained on Days 1, 8 and 50 prior to MTG201 administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04013334
Study type	Interventional
Source	Momotaro-Gene Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 15, 2019
Completion date	January 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06037941` - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma	N/A
Completed	`NCT01675765` - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma	Phase 1
Withdrawn	`NCT04201145` - Pembrolizumab + Defactinib In Pleural Mesothelioma	Phase 1
Completed	`NCT03048474` - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT02369198` - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC	Phase 1
Terminated	`NCT01870609` - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT00886028` - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00272558` - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT02436733` - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM	Phase 2
Completed	`NCT04843007` - Alvopem® (Pemetrexed) Safety Assessment
Completed	`NCT01721018` - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.	Phase 1/Phase 2
Active, not recruiting	`NCT00797719` - Short Neoadjuvant Hemithoracic IMRT for MPM	Phase 1/Phase 2
Completed	`NCT00386815` - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Phase 2
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Completed	`NCT04775446` - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed	`NCT01644994` - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma	Phase 1/Phase 2
Completed	`NCT01865045` - Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Completed	`NCT00571298` - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma	Phase 1
Recruiting	`NCT01343264` - Trimodality Therapy for Malignant Pleural Mesothelioma	N/A
Active, not recruiting	`NCT04162015` - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma	Phase 1